[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Centro de Atencion e Investigacion Medica\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":92},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,43,66],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":25,"briefSummary":27,"conditions":28,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":4},"100580223","phase-4-bioequivalence-study-of-clonazepam-2-mg-tablets-100580223",false,"NCT06834503","Bioequivalence Study of Clonazepam 2 Mg Tablets","Bioequivalence Study of Clonazepam 2 Mg Tablets\u002Fimmediate Release Tablets in Healthy Subjects in a Fasting Condition","Clonazepam","Inclusion Criteria:\n\n* Women and men between 18 and 50 years of age at the time of signing the informed consent form.\n* Women who are not capable of conceiving (To be considered not capable of conceiving she must be at least 1 year postmenopausal or surgically sterile) or who are not pregnant or breastfeeding.\n* Women of childbearing capacity must be using adequate contraception for the past 6 months and agree to continue using adequate contraception for 30 days after signing the consent form.\n* Have been clinically diagnosed as healthy by the study physician.\n* Subjects with the clinical laboratory results requested in the protocol (Table 2) within normal ranges and\u002For fit by medical selection. Current for 3 months.\n* Subjects non-smokers for the last 3 months at the time of signing the informed consent.\n* Having signed the informed consent for the study.\n* Subjects sexually active or of reproductive age must use an effective contraceptive method during and for at least 7 days after the end of the study.\n* Body mass index between 18-30 kg\u002Fm2 at the time of inclusion in the study.\n* Subject with complete contact information (cell phone and\u002For landline contact, address).\n* Subject with a family member or guardian with a contact telephone number.\n* Subject with the availability of time to comply with the scheduled visits and activities.\n* Subject willing to comply with the prohibitions and restrictions specified in this protocol.\n\nExclusion Criteria:\n\n* Subject with a diagnosis of renal, cardiac, hepatic, immunological, dermatological, endocrine, gastrointestinal, neurological or psychiatric disease, compulsive depressive disorder.\n* Subject with diagnosis of hematological disorders, such as anemias and\u002For polycythemia.\n* Subjects with history of gastric surgeries.\n* Permanent or temporary use during the last 5 days prior to the administration of the investigational product of the study of any type of medication either on their own initiative or by medical prescription. Except female patients who are planning regularly with the same contraceptive method in the last 6 months prior to the start of the present study.\n* Pregnant or breastfeeding women (Table 2).\n* Xanthine consumption from coffee, tea or chocolate during the 48 hours prior to hospitalization.\n* Alcohol consumption of more than 16 g per week equivalent to 1 beer or 2 glasses of wine during the 5 days prior to administration of the investigational product.\n* Positive test for consumption of drugs of abuse or psychoactive substances at the time of screening or prior to administration of the investigational product. (Table 2)\n* Known hypersensitivity to the active substance or excipients of the test product.\n* Medical history of angioedema or anaphylaxis.\n* Subject diagnosed with human immunodeficiency virus, hepatitis B (surface antigen) or hepatitis C (surface antigen) positive infection.\n* Having participated in clinical trials in the 4 months prior to the time of signing the informed consent.\n* Have donated blood or reported blood loss greater than 500 mL in the 30 days prior to the time of investigational product administration.\n* Subject with clinically significant acute illness or temperature \\> 38°C within 24 hours prior to administration of the investigational product.\n* Subject with any contraindication to blood collection due to bleeding disorders or thrombocytopenia.",true,"ALL","18 Years","50 Years",{"count":22,"type":23},24,"ESTIMATED","INTERVENTIONAL",[26],"PHASE4","Demonstrate the bioequivalence in 1 study, in fasting condition of two formulations of clonazepam 2 mg Tablets \u002F tablets immediate release in order to establish that there are no significant pharmacokinetic differences.",[29,30],"Healthy","Healthy Donors","NOT_YET_RECRUITING","2025-03-05",{"date":34,"type":35},"2025-03-10","ACTUAL",{"date":37,"type":23},"2025-06-10",{"date":39,"type":23},"2025-11-01",{"name":41,"class":42},"Centro de Atencion e Investigacion Medica","NETWORK",{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":49,"eligibilityCriteria":50,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":51,"targetDuration":4,"studyType":24,"phases":53,"briefSummary":54,"conditions":55,"keywords":56,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":58,"lastUpdatePostDateStruct":59,"startDateStruct":61,"completionDateStruct":63,"leadSponsor":65,"locationsCount":4},"100579366","phase-4-bioequivalence-study-of-pentoxifylline-400-mg-in-healthy-subjects-under-fasting-and-fed-conditions-100579366","NCT06823362","Bioequivalence Study of Pentoxifylline 400 Mg in Healthy Subjects Under Fasting and Fed Conditions","Bioequivalence Study of Pentoxifylline 400 Mg in Sustained Release Tablets in Sustained Release Tablets in Healthy Subjects Under Fasting and Fed Conditions","Pentoxifylline","Inclusion Criteria:\n\n* Men or women between 18 and 50 years of age at the time of signing the informed consent form.\n\ninformed consent. - Women who are not able to conceive, who are not pregnant or breastfeeding. (To be considered not able to conceive she must be at least 1 year postmenopausal).\n\npostmenopausal for at least 1 year or be surgically sterile). Table 2.\n\n* Female participants who are capable of conceiving must be using adequate contraceptive methods for the adequate contraceptive methods for the past 6 months and agree to continue using an adequate method of contraception for the adequate contraceptive method for 30 days after signing the consent form.\n* Have been clinically diagnosed as healthy by the study physician.\n* Subjects with clinical laboratory results within the normal range and\u002For fit by medical medical selection. (Table 2)\n* Subjects were non-smokers for the last 3 months at the time of screening.\n* Having signed the informed consent for the study.\n* Body mass index between 18-30 kg\u002Fm2.\n* Subject with complete contact information (cell phone and\u002For landline contact, address).\n* Subject who has a family member or guardian with a contact telephone number.\n* Subject with the availability of time to comply with the scheduled visits and activities.\n* Subject who is willing to comply with the prohibitions and restrictions specified in this protocol.\n\nExclusion Criteria:\n\n* Subject diagnosed with renal, cardiac, hepatic, immunologic, dermatologic, endocrine, gastrointestinal, neurologic or psychiatric disease, endocrine, gastrointestinal, neurological or psychiatric disease.\n* Subject with diagnosis of hematological disorders, such as anemias and\u002For polycythemia.\n* Subjects with a history of gastric surgery.\n* Permanent or temporary use during the last 15 days of any type of medication. days prior to the administration of the drug, either on their own initiative or by medical prescription.\n\nmedical prescription. Except female patients who are planning regularly with the same contraceptive method.\n\nthe same contraceptive method in the last 6 months prior to the start of the present study.\n\nthe present study.\n\n\\- Smoker in the last 3 months, regardless of the number of cigarettes at the time of selection.\n\nselection.\n\n* Consumption of xanthines from coffee, tea or chocolate during the previous 48 hours.\n* Drinking alcohol in excess of 16 g 15 days prior to administration of the investigational drug.\n\nequivalent to 1 beer or 2 glasses of wine.\n\n* Positive test for the consumption of drugs of abuse or psychoactive substances at the time of screening or prior to administration of the (Table 2).\n* Known hypersensitivity to the active substance or excipients of the test product.\n* Medical history of angioedema or anaphylaxis.\n* Pregnant or lactating woman.\n* Subject diagnosed with human immunodeficiency virus, hepatitis B or hepatitis C positive.\n\nhepatitis C positive.\n\n* Having participated in clinical studies in the 4 months prior to the start of the present study.\n* Having donated blood or reported blood loss of more than 500 mL in the 30 days prior to subject selection.\n\nprior to subject selection.\n\n* Subject has a clinically significant acute illness or temperature \\> 38°C within 24 hours prior to the within 24 hours prior to investigational product administration.\n* Subject has a contraindication to blood collection due to bleeding or thrombotic disorders.\n\nbleeding disorders or thrombocytopenia.",{"count":52,"type":23},40,[26],"Two bioequivalence studies of Pentoxifylline will be carried out in 40 healthy subjects, the first in a fasting condition 40 healthy subjects, the first in fasting condition and the second in postprandial condition.\n\npostprandial condition, the two studies follow the same design: Complete crossover design, randomized, comparative of two study formulations, in single dose of 400 mg of Pentoxifylline sustained release tablets, 2 periods, with a washout time of 7 days between doses, the 7 days between doses, participation as a subject in these studies involves a risk studies involves a higher than minimal risk for subjects.",[29,30],[57],"Bioequivalence","2025-02-13",{"date":60,"type":35},"2025-02-17",{"date":62,"type":23},"2025-04-10",{"date":64,"type":23},"2025-09-30",{"name":41,"class":42},{"id":67,"slug":68,"hasResults":11,"nctId":69,"briefTitle":70,"officialTitle":71,"acronym":72,"eligibilityCriteria":73,"healthyVolunteers":17,"sex":74,"minAge":19,"maxAge":20,"enrollmentInfo":75,"targetDuration":4,"studyType":24,"phases":77,"briefSummary":78,"conditions":79,"keywords":81,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":84,"startDateStruct":86,"completionDateStruct":88,"leadSponsor":90,"locationsCount":91},"100511848","phase-4-bioequivalence-studies-of-dasatinib-100-mg-100511848","NCT05944783","Bioequivalence Studies of Dasatinib 100 Mg","Bioequivalence Studies of Dasatinib 100 Mg Tablets in Healthy Colombian Subjects in Postprandial Condition","BE-Dasatinib","Inclusion Criteria:\n\n* Men of legal age between 18 to 50 years.\n* Have been clinically diagnosed as healthy by the trial doctor.\n* Subjects with clinical laboratory results within normal ranges and\u002For suitable by medical selection.\n* Non-smoking subjects for the last 3 months.\n* Have signed the informed consent.\n* Body mass index between 18-30 kg\u002Fm2\n* Subject with complete contact information (cell phone and\u002For contact landline, address, email).\n* Subject who has a family member or guardian with a contact telephone number.\n* Subject to the availability of time to comply with scheduled visits and activities.\n\nExclusion Criteria:\n\n* Subject with a diagnosis of renal, cardiac, hepatic, immunological, dermatological, endocrine, gastrointestinal, neurological or psychiatric disease.\n* Subjects diagnosed with positive COVID 19\n* Subject diagnosed with hematological disorders, such as anemia and\u002For polycythemia.\n* Subjects with a history of gastric surgeries.\n* Permanent or temporary use during the last 15 days of any type of medication, both on their own initiative and by medical prescription. Except female patients who are planning regularly with the same contraceptive method in the last 6 months prior to the start of this trial.\n* Smoker in the last 3 months, regardless of the number of cigarettes.\n* Consumption of xanthines from coffee, tea or chocolate during the previous 48 hours\n* Drinker of alcohol in more than 16 grams every week equivalent to 1 beer or 2 glasses of wine during the last 15 days.\n* Consumption of drugs of abuse or psychoactive substances reported as a positive test.\n* Known hypersensitivity to the active substance or to the excipients of the test product.\n* Medical history of angioedema or anaphylaxis.\n* Subject diagnosed with human immunodeficiency virus infection, hepatitis B or positive hepatitis C.\n* Have participated in clinical studies in the 4 months prior to the start of this trial.\n* Have donated blood in the 30 days prior to the start of the trial.","MALE",{"count":76,"type":23},46,[26],"A bioequivalence study of Dasatinib will be carried out in 46 healthy subjects, in fed condition, following the complete replicated design, randomized, comparative of 2 sequences, 2 study formulations, in a single dose of 100 mg of Dasatinib tablets \u002F coated tablets, 4 periods. , with a washout time of 7 days between each dose",[80],"Myeloma Multiple",[82],"Dasatinib , fed condition, bioequivalence","2025-02-10",{"date":85,"type":35},"2025-02-12",{"date":87,"type":23},"2025-09-01",{"date":89,"type":23},"2026-04-30",{"name":41,"class":42},1,""]